Close
Publication: EXENATIDE-PD3
12 May 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson鈥檚 disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 鈥楨xenatide-PD3鈥� study
The EXENATIDE-PD3 trial team have published a paper聽in the BMJ Open journal, which is聽available to read on the BMJ Open website .